StockSaints Logo 

Exelixis (EXEL) Earnings Preview For Thursday

Exelixis, Inc.   (EXEL) 

Background:Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer. Its focuses on developing cabozantinib product candidate that inhibits MET, VEGFR2, and RET proteins, which are key drivers of tumor growth, vascularization, and/or metastasis. Exelixis trades an average of 4.1 million shares per day with a marketcap of $716 million

Exelixis is forecast to report WEAK third-quarter earnings after the market closes on November 1, 2012.

The consensus estimate is currently -30 cents a share, falling 89 cents (150.8%) from 59 cents during the same period last year. Analysts are estimating as low as losing 35 cents per share, up to the most optimistic estimate of losing 26 cents per share.

Analyst opinion is mixed with this company. Most of the analysts surveyed don't believe a buy or a sell is currently warranted. Right now, Exelixis has 5 buy recommendations out of 11 analysts covering the company, 6 holds, and no analysts recommend selling. Shareholders have not been rewarded for their patience, shares have fallen 38% in the last year, and the average analyst target price for Exelixis is $6.08.


Rate this article: 
No votes yet
Stock Tickers: EXEL Author Disclosure: NA
Exelixis, Inc.